Pediatric Lipid Screening and Treatment for Cardiovascular Disease Prevention: An Ounce or a Pound?

Current Cardiovascular Risk Reports

Volumn 7, Issue 4, 2013, Pages 261-269

  de Ferranti, Sarah D ^a   Wong, John B ^a   Gooding, Holly ^a   Cohen, Joshua T ^a   Sheldrick, R Christopher ^a   Parsons, Susan K ^a   Leslie, Laurel K ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Cholesterol; Comparative effectiveness; Decision analysis; Dyslipidemia; Screening; Statin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AMNESIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DRUG WITHDRAWAL; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH CARE PLANNING; HUMAN; HYPERTRANSAMINASEMIA; LIFESTYLE MODIFICATION; LIPID ANALYSIS; LIPIDOSIS; META ANALYSIS (TOPIC); MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; SYSTEMATIC REVIEW (TOPIC); WEIGHT REDUCTION;

EID: 84879966139     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0320-2     Document Type: Review

References (82)

1. Li S, Chen W, Srinivasan SR, Bond MG, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study. JAMA. 2003;290(17): 2271-6.
2. Morrison JA, Friedman LA, Gray-McGuire C. Metabolic syndrome in childhood predicts adult cardiovascular disease 25 years later: the Princeton Lipid Research Clinics Follow-up Study. Pediatrics. 2007;120(2): 340-5. In this manuscript, individuals who had cardiovascular risk factors measured during childhood were followed up in adulthood. After 25 years of follow-up, those with higher rates of childhood cardiovascular risk factors had a higher rate of heart disease. This is one of the few studies that links childhood risk factors to actual events.
3. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11): 1138-45.
4. Simon Broome Steering Committee. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ. 1991;303(6807): 893-6.
5. Himmelstein DU, Thorne D, Warren E, Woolhandler S. Medical bankruptcy in the United States, 2007: results of a national study. Am J Med. 2009;122(8): 741-6.
6. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125(1): 188-97.
7. Center for Disease Control and Prevention. Heart disease and stroke prevention addressing the nation's leading killers: at a glance 2011. Atlanta, GA: CDC, National Center for Chronic Disease Prevention and Health Promotion; 2011.
8. Ardern CI, Katzmarzyk PT, Janssen I, et al. Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic. Circulation. 2005;112(10): 1478-85.
9. United States Preventive Services Task Force (USPSTF). Screening for lipid disorders in adults: U. S. Preventive Services Task Force recommendation statement. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2008. p. 1-13.
10. Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia. The Muscatine Study. JAMA. 1990;264(23): 3034-8.
11. Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents. Full report. Bethesda, MD: National Heart, Lung, and Blood Institute, U. S. Department of Health and Human Services; 2011. These comprehensive national pediatric guidelines, released in 2011, call for universal pediatric lipid screening in addition to selective, risk factor based screening. They extend the 2008 AAP screening recommendations and conflict with the 2007 USPSTF guidelines, even though the USPSTF reviewed largely the same body of evidence.
12. Expert Panel on Integrated Guidelines for Cardiovascular Health Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128 Suppl 5: S213-56.
13. Clarke WR, Schrott HG, Leaverton PE, et al. Tracking of blood lipids and blood pressures in school age children: the Muscatine study. Circulation. 1978;58(4): 626-34.
14. Thompson DR, Obarzanek E, Franko DL, et al. Childhood overweight and cardiovascular disease risk factors: the National Heart, Lung, and Blood Institute Growth and Health Study. J Pediatr. 2007;150(1): 18-25.
15. Brown MS, Goldstein JL. Familial hypercholesterolemia: a genetic defect in the low-density lipoprotein receptor. N Engl J Med. 1976;294(25): 1386-90.
16. American Academy of Pediatrics, Committee on Nutrition. Statement on cholesterol. Pediatrics. 1992;90(3): 469-73.
17. American Academy of Pediatrics, Committee on Nutrition. Cholesterol in childhood. Pediatrics. 1998;101(1 Pt 1): 141-7.
18. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122(1): 198-208.
19. Gillman MW, Daniels SR. Is universal pediatric lipid screening justified? JAMA. 2012;307(3): 259-60.
20. Psaty BM, Rivara FP. Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;307(3): 257-8.
21. Mitka M. Some question use of statins to reduce cardiovascular risks in healthy women. JAMA. 2012;307(9): 893-4.
22. Rifai N, Neufeld E, Ahlstrom P, et al. Failure of current guidelines for cholesterol screening in urban African-American adolescents. Pediatrics. 1996;98(3 Pt 1): 383-8.
23. Gillman MW. Screening for familial hypercholesterolemia in childhood. Am J Dis Child. 1993;147(4): 393-6.
24. Shea S, Basch CE, Irigoyen M, et al. Failure of family history to predict high blood cholesterol among hispanic preschool children. Prev Med. 1990;19(4): 443-55.
25. Rainwater DL, McMahan CA, Malcom GT, et al. Lipid and apolipoprotein predictors of atherosclerosis in youth: apolipoprotein concentrations do not materially improve prediction of arterial lesions in PDAY subjects. The PDAY Research Group. Arterioscler Thromb Vasc Biol. 1999;19(3): 753-61.
26. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8): 933-44.
27. Magnussen CG, Venn A, Thomson R, et al. The association of pediatric low- and high-density lipoprotein cholesterol dyslipidemia classifications and change in dyslipidemia status with carotid intima-media thickness in adulthood evidence from the cardiovascular risk in Young Finns study, the Bogalusa Heart study, and the CDAH (Childhood Determinants of Adult Health) study. J Am Coll Cardiol. 2009;53(10): 860-9.
28. Byrne MM, Weissfeld J, Roberts MS. Anxiety, fear of cancer, and perceived risk of cancer following lung cancer screening. Med Dec Making. 2008;28(6): 917-25.
29. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107(2): 256-64.
30. Dunlap BS, Bailes Jr JR. Unlimited energy, restricted carbohydrate diet improves lipid parameters in obese children. Metab Syndr Relat Disord. 2008;6(1): 32-6.
31. Escalante Y, Saavedra JM, Garcia-Hermoso A, Dominguez AM. Improvement of the lipid profile with exercise in obese children: a systematic review. Prev Med. 2012;54(5): 293-301.
32. Kelley GA, Kelley KS. Aerobic exercise and lipids and lipoproteins in children and adolescents: a meta-analysis of randomized controlled trials. Atherosclerosis. 2007;191(2): 447-53.
33. Hjermann I, Velve BK, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981;2(8259): 1303-10.
34. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14): 1279-90.
35. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey. NHANES 2009-2010. U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, Office of Information Services, Hyattsville, MD. http://www. cdc. gov/nchs/nhanes/nhanes2009-2010/nhanes09_10. htm. Accessed 25 May 2012.
36. Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey. Centers for Disease Control and Prevention, Atlanta, GA. 2012. http://www. cdc. gov/nchs/nhanes. htm. Accessed 25 May 2012.
37. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ. 2008;337: a2423.
38. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292(3): 331-7.
39. Prajapati S, Desai CK, Dikshit RK. An evaluation of the effect of atorvastatin on memory and psychomotor functions in hypertensive patients. J Postgrad Med. 2011;57(4): 291-7.
40. Benito-Leon J, Louis ED, Vega S, Bermejo-Pareja F. Statins and cognitive functioning in the elderly: a population-based study. J Alzheimers Dis. 2010;21(1): 95-102.
41. Muldoon MF, Barger SD, Ryan CM, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7): 538-46.
42. Muldoon MF, Ryan CM, Sereika SM, et al. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117(11): 823-9.
43. Mitka M. Statin therapy in primary CVD prevention remains a hot-button topic for some. JAMA. 2011;306(19): 2077-8.
44. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2): 144-52.
45. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA. 2012;307(5): 483-90.
46. Freedman DS, Mei Z, Srinivasan SR, et al. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr. 2007;150(1): 12-7 e2. doi: 10. 1016/j. jpeds. 2006. 08. 042.
47. Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357(23): 2371-9.
48. National Heart, Lung and Blood Institute. Estimate of 10-Year Risk for Coronary Heart Disease Framingham Point Scores. NHLBI. 2013. http://www. nhlbi. nih. gov/guidelines/cholesterol/risk_tbl. htm. Accessed 4 April 2013.
49. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl): S1-8.
50. de Ferranti SD, Daniels SR, Gillman M, et al. Clin Chem. 2012. doi: 10. 1373/clinchem. 2012. 182089.
51. Newman TB, Pletcher MJ, Hulley SB. Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics. 2012;130(2): 349-52. This commentary summarizes the multiple issues taken against the recommendations of the 2011 NHLBI guidelines (also see references #19 and #20). Highlighted issues include the lack of sufficient long-term clinical trial evidence supporting the recommendations and the absence of formal cost-effectiveness analysis evaluating the guideline implications.
52. United States Preventive Services Task Force (USPSTF). Screening for lipid disorders in children: recommendation statement. 2007.
53. United States Preventive Services Task Force (USPSTF). USPSTF procedure manual. 2012. http://www. uspreventiveservicestaskforce. org/uspstf08/methods/procmanual5. htm. Accessed 3 April 2013.
54. United States. Bureau of the Census. 2000 census of population and housing. Summary population and housing characteristics. Washington, DC: U. S. Dept. of Commerce, Economics and Statistics Administration. U. S. G. P. O.; 2002.
55. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart. 2011;97(14): 1175-81.
56. Ademi Z, Watts GF, Juniper A, Liew D. A systematic review of economic evaluations of the detection and treatment of familial hypercholesterolemia. Int J Cardiol. 2013.
57. Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 2002;359(9309): 881-4.
58. Newburger JW, Rosenthal A, Williams RG, et al. Noninvasive tests in the initial evaluation of heart murmurs in children. N Engl J Med. 1983;308(2): 61-4.
59. National Heart Lung and Blood Institute. Shaping the future of research: a strategic plan for the National Heart, Lung, and Blood Institute Bethesda, MD: U. S. Department of Health and Human Services, National Institutes of Health; 2007. Report No.: 07-6150.
60. Institute of Medicine. Initial national priorities for comparative effectiveness research. Consensus report. Washington, DC: The National Academies Press; 2009.
61. Balshem H, Curtis P, Joplin L, et al. Stakeholder involvement in improving comparative effectiveness reviews: AHRQ and the Effective Health Care Program (Prepared by the AHRQ Effective Health Care Program Product Development Work Group under Contract No. HHSA 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; 2011 Contract No.: 11-EHC079-EF.
62. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA. 2012;307(15): 1583-4.
63. Committee on Quality of Health Care in America, Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, D. C: National Academy Press; 2001.
64. Wilkerson L, Fung CC, May W, Elliott D. Assessing patient-centered care: one approach to health disparities education. J Gen Intern Med. 2010;25 Suppl 2: S86-90.
65. Sepucha K, Mulley Jr AG. A perspective on the patient's role in treatment decisions. MCRR. 2009;66(1 Suppl): 53S-74S.
66. Elwyn G, Frosch D, Volandes AE, et al. Investing in deliberation: a definition and classification of decision support interventions for people facing difficult health decisions. Med Decis Making. 2010;30(6): 701-11.
67. Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4): 436-8. Emphasizes the importance of engaging relevant stakeholders to directly inform guideline development by incorporating their preferences, values, wants and needs. Also calls for greater inclusion of preferences in evidence-based medicine and research.
68. Arnett JJ. Emerging adulthood. A theory of development from the late teens through the twenties. Am Psychol. 2000;55(5): 469-80.
69. Kimm SY, Payne GH, Stylianou MP, et al. National trends in the management of cardiovascular disease risk factors in children: second NHLBI survey of primary care physicians. Pediatrics. 1998;102(5): E50.
70. Eaton CB, Galliher JM, McBride PE, et al. Family physician's knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med. 2006;19(1): 46-53.
71. Foley KA, Denke MA, Kamal-Bahl S, et al. The impact of physician attitudes and beliefs on treatment decisions: lipid therapy in high-risk patients. Med Care. 2006;44(5): 421-8.
72. Cook S, Drum ML, Kirchhoff AC, et al. Providers' assessment of barriers to effective management of hypertension and hyperlipidemia in community health centers. J Health Care Poor Underserved. 2006;17(1): 70-85.
73. Dailey R, Schwartz KL, Binienda J, et al. Challenges in making therapeutic lifestyle changes among hypercholesterolemic African-American patients and their physicians. J Natl Med Assoc. 2006;98(12): 1895-903.
74. Doroodchi H, Abdolrasulnia M, Foster JA, et al. Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events. BMC Fam Pract. 2008;9: 42. doi: 10. 1186/1471-2296-9-42.
75. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111(4): 499-510.
76. Nieuwlaat R, Schwalm JD, Khatib R, Yusuf S. Why are we failing to implement effective therapies in cardiovascular disease? Eur Heart J. 2013.
77. Bayley MT, Hurdowar A, Richards CL, et al. Barriers to implementation of stroke rehabilitation evidence: findings from a multi-site pilot project. Disabil Rehabil. 2012;34(19): 1633-8.
78. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York, NY: Oxford University Press, Inc.; 2000.
79. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute For Clinical Excellence (NICE). Lancet. 2002;360(9334): 711-5.
80. Patient Centered Outcomes Research Institute Methodology Committee. Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI). December 14, 2012. http://www. pcori. org/assets/PCORI-Methodology-Committee-Research-Recommendations. pdf. Accessed 5 Jan 2013.
81. Carroll AE, Downs SM. Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr. 2009;155(1): 21-5. 5 e1-5.
82. Cohen JT, Neumann PJ. Using decision analysis to better evaluate pediatric clinical guidelines. Health affairs (Project Hope). 2008;27(5): 1467-75.